PROVIDENCE – EpiVax and French pharmaceutical company Ipsen recently announced a collaborative project to combat neurotoxins with novel biologic therapeutics. Small, but nimble EpiVax is an innovation leader in the global market.
EpiVax will present results of research already conducted for the collaboration at the upcoming Interagency Botulism Research Coordinating Committee conference on botulinum neurotoxins.
Seifert Systems Invests in Energy Efficiency to Strengthen Operations
For manufacturers, energy is more than just another operating expense. It plays a critical role…
Learn More
Anne De Groot, CEO of EpiVax, said that the company’s partnership with Ipsen was a significant step, in terms of the products that will be brought to market.
“It capitalizes on technological advances and promises to bring better drugs, with defined mechanisms of action and well-known safety and efficacy profiles, to market,” De Groot said in a statement.
